Related Experiment Video

Updated: Jul 5, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future

J D Isaacs1

  • 1Musculoskeletal Research Group and Wilson Horne Immunotherapy Centre, Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, UK. j.d.isaacs@ncl.ac.uk

Rheumatology (Oxford, England)
|May 27, 2008
PubMed

Insights

Rheumatoid arthritis (RA) is a T-cell-mediated autoimmune disease. Emerging therapies like co-stimulation blockade offer new hope for targeted immune regulation and treatment.

Area of Science:

  • Immunology
  • Autoimmune Diseases
  • Rheumatology

Background:

  • Rheumatoid arthritis (RA) is increasingly recognized as a T-cell-mediated autoimmune condition.
  • Previous therapeutic strategies, including CD4 monoclonal antibodies (mAbs), were limited by the absence of autoreactivity biomarkers.
  • Recent advancements in understanding immune regulation have led to effective treatments like co-stimulation blockade for RA.

Purpose of the Study:

  • To review the progress in understanding and treating rheumatoid arthritis as an autoimmune disease.
  • To highlight the potential of novel immunotherapeutic approaches for RA.
  • To discuss the future prospects of immune programming in managing autoimmune pathologies.

Main Methods:

  • Review of accumulating evidence on RA pathogenesis.
  • Analysis of therapeutic strategies, including CD4 mAbs and co-stimulation blockade.
  • Exploration of emerging treatment paradigms in immunology.

Main Results:

  • Co-stimulation blockade has shown efficacy in treating RA.
  • Improved mechanistic understanding of immune regulation is advancing RA treatment.
  • New therapies like non-mitogenic anti-CD3 mAbs, autoantigenic peptides, and cellular therapies show promise.

Conclusions:

  • Targeted immune programming offers a promising future for controlling RA immunopathology.
  • While challenges remain, advancements in immunotherapy are transforming RA treatment.
  • Specific and vigorous curtailment of immunopathology is becoming increasingly achievable.

More Related Videos

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity10:10

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...